Main Menu

CASPS

A phase II trial of cediranib in the treatment of patients with alveolar soft part sarcoma.

Disease site: Sarcoma

Treatment modality: Systemic therapy

Status: In follow-up

Trial details

CASPS is a two-arm, randomised, double blind, international, multicentre phase II trial to confirm the ability of the anti-angiogenic drug cediranib to halt disease progression in patients with metastatic alveolar soft part sarcoma.

Thirty-six patients will be recruited from 12 sites in the UK, Australia and Spain over a five-year period. Patients will receive either cediranib or placebo until 24 weeks post-randomisation, when treatment will be unblinded and all patients on placebo and those who have not progressed on active treatment will begin or continue taking cediranib. Treatment will continue until objective disease progression and participants will be followed up for life.

Further information

Chief Investigator: Professor Ian JudsonThe Royal Marsden NHS Foundation Trust

ICR-CTSU Scientific Lead: Professor Judith Bliss

Trial management contact: [email protected] 

ISRCTN: 3733470

Sponsor: The Institute of Cancer Research

Funding: Cancer Research UK (CRUK/10/021), AstraZenenca

Further information including recruitment progress is available from the following link:

UK Clinical Trials Gateway 

Patient friendly information is available from the following link:

CancerHelp UK 

Publications and presentations

Judson I, Snowdon C, Fox L, Kernaghan S, Morden J, Bliss J; on behalf of the CASPS Trial Management Group. Trial in progress: a phase II, international trial of cediranib in the treatment of patients with alveolar soft part sarcoma (CASPS) C2130/A12118. Presented at: 10th National Cancer Research Institute Cancer Conference; 2014 Nov 2-5; Liverpool, UK.

Judson I, Snowdon C, Fox L, Kernaghan S, Morden J, Bliss J; on behalf of the CASPS Trial Management Group. Trial in progress: a phase II international trial of cediranib in the treatment of patients with alveolar soft part sarcoma (CASPS) C2130/A12118. Presented at: British Sarcoma Group Conference; 2014 Feb 26-28; Nottingham, UK.

Judson I, Olmos D, Snowdon C, Fox L, Kernaghan S, Morden J, Bliss J; on behalf of the CASPS Trial Management Group. Trial in progress: a phase II international trial of cediranib in the treatment of patients with aveolar soft part sarcoma (CASPS) CRUK ref: C2130/A12118. Presented at: British Sarcoma Group Conference; 2012 Feb 29-Mar 2; Oxford, UK. 

Clinical trials

Division of Clinical Studies

The division carries out or coordinates high-quality trials and translational research at both an early phase – typically to test new targeted drugs – and a later stage.